Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 676 across all filing types
Latest filing 2025-06-23 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which mandates disclosure of material events. The content is purely an announcement of scheduled meetings with investors and analysts, without any financial data, report, or detailed presentation. The document length is short (1732 characters), and it does not contain financial statements or detailed analysis. Therefore, it is not a financial report, earnings release, or investor presentation. It fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about investor meetings, which does not fit other specific categories.
2025-06-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements, 2015, indicating it is a regulatory announcement. The content is a schedule of meetings rather than a financial report or presentation. The document length is short (1828 characters), and it does not contain financial data, management discussion, or detailed presentations. It is an announcement of meetings, not a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-06-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events. The content is a schedule of upcoming meetings with investors and analysts, not a financial report, earnings release, or any detailed presentation. The document length is short (2029 characters) and it serves as an announcement of meetings rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-06-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which pertains to disclosure of material events. The content is about upcoming investor meetings and does not contain financial results, detailed presentations, or reports. It is an announcement of scheduled meetings rather than a report or transcript of the meetings. Therefore, it fits best under Investor Presentation (IP) category, as it relates to investor engagement activities. However, since it only provides a schedule and not a detailed presentation, it is more accurately classified as a Regulatory Filing (RNS) because it is a regulatory disclosure of material event information without substantive financial or strategic content. The document length is short (1826 characters), and it is an announcement rather than a report or transcript. Hence, the best classification is Regulatory Filings (RNS).
2025-06-09 English
General Updates
Legal Proceedings Report Classification · 95% confidence The document is an update letter addressed to stock exchanges regarding the final report from the Agence nationale de sécurité du médicament et des produits de santé (ANSM) following a Good Manufacturing Practices (GMP) inspection at a manufacturing facility. It details observations from the inspection, corrective actions planned, and confirms no disruption to operations. The document references regulatory compliance under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes an annexure with details about the authority, report, and impact. The content is an announcement of regulatory inspection results and corrective plans, not a full audit report, annual report, or financial statement. It is a regulatory update on legal/regulatory matters affecting the company. Therefore, it fits best under Legal Proceedings Report (LTR) as it relates to regulatory inspection findings and compliance actions.
2025-06-04 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Gland Pharma has received USFDA approval for a specific drug product, Angiotensin II Acetate Injection 2.5 mg/mL. It references regulatory compliance with SEBI Listing Obligations and Disclosure Requirements, indicating it is an official announcement to stock exchanges. The content focuses on the approval news and product details, without any financial statements, management discussion, or detailed report data. The document length is 3782 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. It is not a voting result, board change, or legal proceeding. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about a material event (FDA approval) that does not fit into other specific categories like earnings or capital updates.
2025-06-04 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.